MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy

被引：222

作者：

Pope, WB

Lai, A

Nghiemphu, P

Mischel, P

Cloughesy, TF

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Med Ctr, Dept Radiol Sci, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA

来源：

NEUROLOGY | 2006年 / 66卷 / 08期

关键词：

D O I：

10.1212/01.wnl.0000208958.29600.87

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Bevacizumab is a monoclonal antibody that neutralizes vascular endothelial growth factor (VEGF), the key mediator of tumor angiogenesis. VEGF impacts endothelial cell permeability, activation, survival, proliferation, invasion and migration, all of which play a role in tumor progression. In combination with chemotherapy, bevacizumab may improve survival in patients with metastatic colorectal cancer, breast cancer, and lung cancer. (1) Malignant gliomas express VEGF receptors, (2) and glioblastoma cell lines have been shown to secrete VEGF. (3) Therefore, we assessed the early imaging effects of bevacizumab coupled with etoposide, carboplatin, or cpt-11 on recurrent malignant (Grade III and Grade IV) gliomas using contrast-enhanced MRI.

引用

收藏

页码：1258 / 1260

页数：3

相关论文

共 10 条

[1] Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer [J].

Emmanouilides C. ;

Pegram M. ;

Robinson R. ;

Hecht R. ;

Kabbinavar F. ;

Isacoff W. .

Techniques in Coloproctology, 2004, 8 (Suppl 1) :S50-S52

[2] Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis [J].

Hicklin, DJ ;

Ellis, LM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) :1011-1027

[3]

Hoeckel Michael, 1996, Cancer Research, V56, P4509

[4] Expression of VEGF and its receptors in different brain tumors [J].

Huang, HG ;

Held-Feindt, J ;

Buhl, R ;

Mehdorn, HM ;

Mentlein, R .

NEUROLOGICAL RESEARCH, 2005, 27 (04) :371-377

[5] Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478 [J].

Jordan, BF ;

Runquist, M ;

Raghunand, N ;

Baker, A ;

Williams, R ;

Kirkpatrick, L ;

Powis, G ;

Gillies, RJ .

NEOPLASIA, 2005, 7 (05) :475-485

[6] hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines [J].

Masi, A ;

Becchetti, A ;

Restano-Cassulini, R ;

Polvani, S ;

Hofmann, G ;

Buccoliero, AM ;

Paglierani, M ;

Pollo, B ;

Taddei, GL ;

Gallina, P ;

Di Lorenzo, N ;

Franceschetti, S ;

Wanke, E ;

Arcangeli, A .

BRITISH JOURNAL OF CANCER, 2005, 93 (07) :781-792

[7]

Pope WB, 2005, AM J NEURORADIOL, V26, P2466

[8] MRI of high-grade glial tumors: Correlation between the degree of contrast enhancement and the volume of surrounding edema [J].

Pronin, IN ;

Holodny, AI ;

Petraikin, AV .

NEURORADIOLOGY, 1997, 39 (05) :348-350

[9] Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis [J].

van der Flier, M ;

Coenjaerts, FE ;

Mwinzi, PN ;

Rijkers, E ;

Ruyken, M ;

Scharringa, J ;

Kimpen, JLL ;

Hoepelman, AIM ;

Geelen, SPM .

JOURNAL OF NEUROIMMUNOLOGY, 2005, 160 (1-2) :170-177

[10] A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse [J].

Yung, WKA ;

Albright, RE ;

Olson, J ;

Fredericks, R ;

Fink, K ;

Prados, MD ;

Brada, M ;

Spence, A ;

Hohl, RJ ;

Shapiro, W ;

Glantz, M ;

Greenberg, H ;

Selker, RG ;

Vick, NA ;

Rampling, R ;

Friedman, H ;

Phillips, P ;

Bruner, J ;

Yue, N ;

Osoba, D ;

Zaknoen, S ;

Levin, VA .

BRITISH JOURNAL OF CANCER, 2000, 83 (05) :588-593